ClinicalTrials.gg
CompletedNCT02341638Updated Mar 31, 2017

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

A Phase 1 interventional study of BMS-986141 and Placebo in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-31.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing aspirin in Thrombosis — 2 open to participants now, 3 under way, none of them phase 3. Aspirin · Thrombosis.

Enrollment
12th of 28
148 · median 106
Started
2014
with 3 others
Phase 1
4 of 28
none open now
Registered
14th of 28
by date
Lead sponsor
3 of 28
Bristol-Myers Squibb

Among the 28 studies testing aspirin in Thrombosis, this one is the 12th largest by enrollment, is one of 4 that started in 2014, is one of 4 in phase 1, and was the 14th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

2 of the 28 studies testing aspirin in Thrombosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing aspirin in Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple oral doses of BMS-986141 in healthy subjects.

Read the detailed description

Maximum Age:

Part A SAD 65 years

Part B MAD 75 years

Part C MAD Japanese 75 years

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  1. Healthy male and female subjects as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
  2. (BMI) of 18 to 32 kg/m2, inclusive. BMI=Weight (kg)/[height(m)]2
  3. Women who are not of (i.e., who are or surgically sterile) and men, ages 18 to 75, inclusive

Exclusion criteria

Exclusion Criteria:

  1. Concurrent or use within 2 weeks of study drug administration, of marketed or , drugs as specified in protocol
  2. Other protocol-defined exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Part A Panel 1: BMS-986141 or Placebo

    BMS-986141 or Placebo single dose by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part A Panel 2: BMS-986141 or Placebo

    BMS-986141 or Placebo single dose by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part A Panel 3: BMS-986141 or Placebo

    BMS-986141 or Placebo single dose by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part A Panel 4: BMS-986141 or Placebo

    BMS-986141 or Placebo single dose by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part A Panel 5: BMS-986141 or Placebo

    BMS-986141 or Placebo single dose by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part A Panel 6: BMS-986141 or Placebo

    BMS-986141 or Placebo single dose by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part A Panel 7: BMS-986141

    Single dose by mouth as specified

    Drug: BMS-986141

  • Experimental
    Part A Panel 8: BMS-986141

    Single dose by mouth as specified

    Drug: BMS-986141

  • Experimental
    Part B Panel 1: BMS-986141 or Placebo

    BMS-986141 or Placebo by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part B Panel 2: BMS-986141 or Placebo

    BMS-986141 or Placebo by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part B Panel 3: BMS-986141 or Placebo

    BMS-986141 or Placebo by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part C Panel 1: BMS-986141 or Placebo

    BMS-986141 or Placebo by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part C Panel 2: BMS-986141 or Placebo

    BMS-986141 or Placebo by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part C Panel 3: BMS-986141 or Placebo

    BMS-986141 or Placebo by mouth as specified

    Drug: BMS-986141 · Drug: Placebo

  • Experimental
    Part D Panel 1: BMS-986141 and Aspirin

    BMS-986141 and Aspirin by mouth as specified

    Drug: BMS-986141 · Drug: Aspirin

  • Placebo comparator
    Part D Panel 1: Placebo matching BMS-986141 and Aspirin

    BMS-986141 placebo and Aspirin by mouth as specified

    Drug: Placebo · Drug: Aspirin

  • Experimental
    Part E Panel 1: BMS-986141 and Itraconazole

    BMS-986141 and Itraconazole by mouth as specified

    Drug: BMS-986141 · Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Safety measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Serious adverse event (SAE) Adverse event (AE) Electrocardiogram (ECG)

    Time frame: Up to 30 days post discontinuation of dosing or last participation in the study

  2. Tolerability measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Time frame: Up to 30 days post discontinuation of dosing or last participation in the study

  3. Safety measured by percent of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Time frame: Up to 30 days post discontinuation of dosing or last participation in the study

  4. Tolerability measured by percent of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Time frame: Up to 30 days post discontinuation of dosing or last participation in the study

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551

    Time frame: Up to Day 14

  2. Time of maximum observed plasma concentration (Tmax) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551

    Time frame: Up to Day 14

  3. Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986141, BMT-162853, BMT-162856, and BMT-181551

    Time frame: Up to Day 14

  4. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986141, BMT-162853, BMT-162856, and BMT-181551

    Time frame: Up to Day 14

  5. Concentration at 24 hours (C24) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551

    Time frame: Up to Day 14

  6. Half-life (T-HALF) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551

    Time frame: Up to Day 14

  7. Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986141, BMT-162853, BMT-162856, and BMT-181551

    Time frame: Up to Day 14

  8. AUC accumulation index (AI_AUC) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551; ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose

    Time frame: Up to Day 14

  9. Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff_AUC) of BMS-986141, BMT-162853, BMT-162856, and BMT-181551

    Time frame: Up to Day 14

  10. MR_Cmax of BMT-162853, BMT-162856, and BMT-181551

    Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax)

    Time frame: Up to Day 14

  11. MR_AUC(INF) of BMT-162853, BMT-162856, and BMT-181551

    Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight \[MR_AUC(INF)\]

    Time frame: Up to Day 14

  12. MR_AUC(0-T) of BMT-162853, BMT-162856, and BMT-181551

    Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight \[MR_AUC(0-T)\]

    Time frame: Up to Day 14

  13. MR_AUC(TAU) of BMT-162853, BMT-162856, and BMT-181551

    Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight \[MR_AUC(TAU)\]

    Time frame: Up to Day 14

  14. Safety of multiple doses of BMS-986141 and aspirin in healthy subjects

    Safety measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations.

    Time frame: Up to 30 days post discontinuation of dosing or last participation in the study

  15. Tolerability of multiple doses of BMS-986141 and aspirin in healthy subjects

    Tolerability measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Time frame: Up to 30 days post discontinuation of dosing or last participation in the study

  16. Safety of BMS-986141 and itraconazole in healthy subjects

    Safety measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Time frame: Up to 30 days post discontinuation of dosing or last participation in the study

  17. Tolerability of BMS-986141 and itraconazole in healthy subjects

    Tolerability measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Time frame: Up to 30 days post discontinuation of dosing or last participation in the study

07

Study locations

2 sites
  • West Coast Clinical Trials, Llc
    Cypress, California 90630, United States
  • Ppd Development, Lp
    Austin, Texas 78744, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2015
First posted
Jan 19, 2015
Start
Sep 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Last update
Mar 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02341638
Responsible party
Sponsor
First posted
Jan 19, 2015
Start date
Sep 2014
Primary completion
Sep 2015
Completion
Sep 2015
Last update
Mar 31, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BMS-986141 · Aspirin

Start the discussion